Comprehensive End-Stage Renal Disease Care Model

Comprehensive End-Stage Renal Disease Care Model
Name	Comprehensive End-Stage Renal Disease Care Model
Type	Healthcare payment and delivery model
Established	2015
Administrator	Centers for Medicare & Medicaid Services
Region	United States

Comprehensive End-Stage Renal Disease Care Model

The Comprehensive End-Stage Renal Disease Care Model was a United States federal demonstration that aligned clinical care and payment for people with End-stage renal disease under the auspices of the Centers for Medicare & Medicaid Services and tied to broader reforms such as the Patient Protection and Affordable Care Act and initiatives from the Department of Health and Human Services. It sought to integrate services across settings associated with Dialysis provision, Kidney transplantation, and chronic disease management, promoting coordination among providers including Nephrology groups, Hospitals, and private Dialysis clinics.

Background and Objectives

The Model originated from federal policy debates involving the Medicare Program, the Center for Medicare and Medicaid Innovation, and stakeholders such as the American Society of Nephrology, the Renal Physicians Association, and provider chains like Fresenius Medical Care and DaVita Inc.. Motivations referenced policy history including the Social Security Amendments of 1972 which extended entitlement for dialysis, the rise of large dialysis organizations in the 1990s, and subsequent quality initiatives such as the End-Stage Renal Disease Prospective Payment System and the MACRA era reforms. Objectives emphasized reducing preventable hospitalizations, increasing transplantation and home dialysis uptake, and coordinating post-acute care with partners such as Accountable Care Organizations, Hospice providers, and specialty pharmacies.

Program Structure and Participation

Participation was organized through voluntary ESRD Seamless Care Organizations that contracted with Medicare to manage care for a defined beneficiary population. Eligible entities often included integrated care networks, nephrology practices affiliated with academic centers like Johns Hopkins Hospital or Mayo Clinic, community providers, and large provider firms with ties to UnitedHealth Group or regional health systems such as Kaiser Permanente. Contracts specified care management roles for Nephrologists, Registered nurses, social workers, and clinical pharmacists; they also engaged transplant centers such as Cleveland Clinic and pediatric programs like Children's Hospital of Philadelphia for transition planning.

Clinical Care and Quality Measures

Clinical protocols targeted anemia management, vascular access optimization, infection control, and dialysis adequacy aligned with measures promulgated by the Centers for Disease Control and Prevention, the National Quality Forum, and specialty societies including the American Society of Nephrology and National Kidney Foundation. Quality metrics encompassed rates of catheter use versus arteriovenous fistula placement, hospitalization frequency, readmission rates tracked under Hospital Readmissions Reduction Program, and transplantation referral rates tied to centers such as Massachusetts General Hospital and Stanford Health Care. Cross-sector performance leveraged electronic health records interoperable with standards from Office of the National Coordinator for Health Information Technology and registry data similar to the United States Renal Data System.

Payment Model and Financial Incentives

The model combined capitated management fees, shared savings arrangements, and pay-for-performance incentives influenced by precedent programs like the Bundled Payments for Care Improvement initiative and the Medicare Shared Savings Program. Risk adjustment referenced demographic and clinical tools used by Social Security Administration data analysts and actuarial methods from consulting firms that advise Centers for Medicare & Medicaid Services. Financial incentives aimed to reward reductions in avoidable inpatient care, increased transplantation comparable to volumes at centers like UCLA Health and Mount Sinai Health System, and uptake of home modalities consistent with policies from the Health Resources and Services Administration.

Outcomes, Evaluations, and Impact

Evaluations by independent analysts and federal agencies compared participating organizations to national benchmarks established in the United States Renal Data System and academic studies published by investigators affiliated with institutions such as Harvard Medical School, University of California, San Francisco, and Yale School of Medicine. Reported impacts included mixed reductions in hospitalization rates, variable increases in home dialysis initiation similar to programs at Mayo Clinic and Cleveland Clinic, and modest changes in transplantation waitlisting akin to targeted interventions at Johns Hopkins Hospital. Economic analyses referenced methodologies used in evaluations of the Affordable Care Act demonstrations and drew on comparative work from The Brookings Institution and Kaiser Family Foundation.

Implementation Challenges and Policy Considerations

Challenges mirrored those in other value-based care efforts overseen by the Center for Medicare and Medicaid Innovation and included issues with attribution, regulatory constraints from Centers for Medicare & Medicaid Services, information sharing across entities like Health Information Exchanges, and workforce limitations highlighted by advocacy groups such as the American Nurses Association. Policy debates involved the balance between incentives and access raised in hearings before the United States Congress and policy briefs from think tanks including The Commonwealth Fund and Urban Institute. Future considerations referenced coordination with broader payment reforms under Medicaid waivers, implications for pharmaceutical procurement by large dialysis organizations, and alignment with transplantation initiatives run by United Network for Organ Sharing.

Category:Healthcare reform in the United States